Olanzapine-associated dose-dependent alterations for weight and metabolic parameters in a prospective cohort.
Fiche du document
- doi: 10.1111/bcpt.13715
- issn: 1742-7835
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1111/bcpt.13715
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/35150056
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1742-7843
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_995572119F819
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Gaining weight Gain of weightCiter ce document
G. Schoretsanitis et al., « Olanzapine-associated dose-dependent alterations for weight and metabolic parameters in a prospective cohort. », Serveur académique Lausannois, ID : 10.1111/bcpt.13715
Métriques
Partage / Export
Résumé
Metabolic abnormalities have been associated with olanzapine treatment. We assessed if olanzapine has dose-dependent effects on metabolic parameters with changes for weight, blood pressure, lipid and glucose profiles being modelled using linear mixed-effects models. The risk of metabolic abnormalities including early weight gain (EWG) (≥5% during first month) was assessed using mixed-effects logistic regression models. In 392 olanzapine-treated patients (median age 38.0 years, interquartile range [IQR] = 26.0-53.3, median dose 10.0 mg/day, IQR = 5.0-10.0 for a median follow-up duration of 40.0 days, IQR = 20.7-112.2), weight gain was not associated with olanzapine dose (p = 0.61) although it was larger for doses versus ≤10 mg/day (2.54 ± 5.55 vs. 1.61 ± 4.51% respectively, p = 0.01). Treatment duration and co-prescription of >2 antipsychotics, antidepressants, benzodiazepines and/or antihypertensive agents were associated with larger weight gain (p < 0.05). Lower doses were associated with increase in total and HDL cholesterol and systolic and diastolic blood pressure (p < 0.05), whereas higher doses were associated with glucose increases (p = 0.01). Patients receiving >10 mg/day were at higher EWG risk (odds risk: 2.15, 1.57-2.97). EWG might be prominent in high-dose olanzapine-treated patients with treatment duration and co-prescription of other medications being weight gain moderators. The lack of major dose-dependent patterns for weight gain emphasizes that olanzapine-treated patients are at weight gain risk regardless of the dose.